Table 1.

Current antifungal agents available for the therapy of systemic mycosis.

Antifungal spectrum	AMB	5FC	FLU	ITR	VOR	POS	ISA	CAS	MIC	ANI
Candida albicans	++	++	++	++	++	++	++	++	++	++
Candida glabrata	++	++	+	+	++	++	++	+	+	+
Candida parapsilosis	++	++	++	++	++	++	++	++	++	++
Candida tropicalis	++	++	++	++	++	++	++	++	++	++
Candida krusei	++	+	–	+	++	++	++	++	++	++
Candida lusitaniae	–	++	++	++	++	++	++	++	++	++
Aspergillus fumigatus	++	–	–	+	++	++	++	+	+	+
Cryptococcus neoformans	++	++	++	++	++	++	++	–	–	–
Mucorales	++	–	–	–	–	++	++	–	–	–
Fusarium spp.	+	–	–	+	++	++	++	–	–	–
Scedosporium spp.	+	–	–	+	+	+	+	–	–	–
Blastomyces dermatitidis	++	–	+	++	++	++	++	–	–	–
Coccidioides immitis	++	–	++	++	++	++	++	–	–	–
Histoplasma capsulatum	++	–	+	++	++	++	++	–	–	–
Class	Polyene	Pyrimidine	Azole					Echinocandins
Target	Ergosterol	Nucleic acid	Ergosterol					Cell wall
Administration	Intravenous	Oral	Oral/Intravenous					Intravenous
Side Effects	Infusion reactions, hepatotoxicity, nephrotoxicity	Bone marrow suppression, liver toxicity	Gastrointestinal upset, hepatotoxicity, liver failure					Infusion reactions, gastrointestinal upset, headache, liver toxicity

5FC, flucytosine; AMB, amphotericin B; ANI, anidulafungin; CAS, caspofungin; FLU, fluconazole; ISA, isavuconazole; ITR, itraconazole; MIC, micafungin; POS, posaconazole; VOR, voriconazole.

Adapted from Nett and Andes (2016).